The U.S. Nuclear Regulatory Commission is in the process of rescinding or revising guidance and policies posted on this webpage in accordance with Executive Order 14151 Ending Radical and Wasteful Government DEI Programs and Preferencing, and Executive Order 14168 Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government. In the interim, any previously issued diversity, equity, inclusion, or gender-related guidance on this webpage should be considered rescinded that is inconsistent with these Executive Orders.

§ 26.133 Cutoff levels for drugs and drug metabolites.

Subject to the provisions of § 26.31(d)(3)(iii), licensees and other entities may specify more stringent cutoff levels for drugs and drug metabolites than those in Table 1 to § 26.133 and, in such cases, may report initial test results for only the more stringent cutoff levels. Otherwise, the following cutoff levels must be used for initial testing of urine specimens to determine whether they are negative or positive for the indicated drugs and drug metabolites:

TABLE 1 TO § 26.133—URINE, INITIAL TEST CUTOFF LEVELS FOR DRUGS AND DRUG METABOLITES

Drugs or drug metabolites Cutoff level
[nanograms (ng)/mL]
Marijuana metabolites 50
Cocaine metabolites 150
Opioids:  
      Codeine/Morphine 1 2000
      Hydrocodone/Hydromorphone 300
      Oxycodone/Oxymorphone 100
      6-acetylmorphine (6–AM) 10
Phencyclidine (PCP) 25
Amphetamines: 2  
      AMP/MAMP 3 500
      MDMA 4/MDA 5 500

1 Morphine is the target analyte for codeine/morphine testing.

2 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.

3 Methamphetamine (MAMP) is the target analyte for amphetamine (AMP)/MAMP testing.

4 Methylenedioxymethamphetamine.

5 Methylenedioxyamphetamine.

[73 FR 17205 Mar. 31, 2008; 87 FR 71459, Nov. 22, 2022]

Page Last Reviewed/Updated Thursday, December 22, 2022